member
Harry CHEN
Co-Founder & CFO, E3A Healthcare Pte Limited
My name is Harry Chen, and I am the Co-Founder and Chief Financial Officer of E3A Healthcare. I began my entrepreneurial journey in 2018, foundingQuit Labs, a digital health platform that helped people quit smoking using cognitive behavioral therapy (CBT). After scaling the business across Asia anddemonstrating strong clinical efficacy, I successfully exited the company in 2021 through a sale to a regional pharmaceutical firm. With a background infinance (CPA) and strategy—bolstered by degrees from UC Berkeley and an onging MBA from HKUST—I’ve always been driven by the belief thathealthtech innovation should be both impactful and commercially sustainable. In 2021, I joined forces with Dr. Shawn Li and a team of researchers fromthe National University of Singapore to co-found E3A Healthcare, recognizing a major gap in women’s healthcare and a rare opportunity to reshape itwith AI and biosensor-driven technologies. At E3A, I lead fundraising, business development, and global strategy, having raised over USD $6 million todate and spearheaded our entry into markets including Hong Kong and Southeast Asia. Seeing our solutions serve over 300,000 families worldwide hasreaffirmed my commitment to building healthcare innovations that matter.
Company Description
E3A Healthcare is a pioneering medtech company committed to transforming women’s and neonatal health through non-invasive, AI-powered medicaldevices. Founded in 2019 at the National University of Singapore, E3A addresses long-standing gaps in healthcare for women by combining advancedbiosensor technology, real-time AI diagnostics, and user-friendly design to deliver smarter, safer, and more accessible care. Our core product suiteincludes Modoo, the world’s first AI-driven, non-ultrasound fetal monitor; Bilimonitor, an at-home jaundice detection and treatment system for newborns;and Nora, a first-in-class, non-drug therapy for endometriosis and adenomyosis based on transcutaneous auricular vagus nerve stimulation (taVNS).Together, these products serve a global women’s health market valued at over USD $40 billion, and have already impacted more than 300,000 families.With regulatory approvals from the FDA, NMPA, and Hong Kong authorities, and over USD $2 million in 2024 revenue (projected $4M+ in 2025), E3A isscaling quickly across Asia and global markets. Headquartered at Hong Kong Science and Technology Park, we’re backed by top investors includingNUS, China Resources Enterprise, and Hong Kong X Fund. E3A is not just building devices—we’re building the future of women’s healthcare.